AbbVie launches new oncology drug Elahere in US and EU for ovarian cancer.

{
  "signal_id": "c475ba06-b264-4c5d-a9b1-7d78a4caf855",
  "signal_type": "sec-10k",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-02-24T09:18:27.385+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "detail": "The launch of Elahere, an antibody-drug conjugate (ADC), marks a significant addition to AbbVie's oncology portfolio. It targets a specific, hard-to-treat patient population in major global markets, representing a new revenue opportunity and focus area for commercial support.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "AbbVie launches new oncology drug Elahere in US and EU for ovarian cancer.",
    "excerpts": "Elahere. Elahere (mirvetuximab soravtansine-gynx) is an antibody-drug conjugate (ADC) used to treat certain types of cancer. Elahere is approved in both the United States and the European Union for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm",
    "filing_date": "2026-02-20",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "United States",
      "European Union"
    ],
    "technologies_mentioned": [
      "antibody-drug conjugate (ADC)"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/c475ba06-b264-4c5d-a9b1-7d78a4caf855 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'